ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Purchased by New York State Teachers Retirement System

New York State Teachers Retirement System raised its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 0.9% during the 4th quarter, Holdings Channel reports. The firm owned 22,380 shares of the specialty pharmaceutical company’s stock after acquiring an additional 200 shares during the quarter. New York State Teachers Retirement System’s holdings in ANI Pharmaceuticals were worth $1,234,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Teachers Retirement System of The State of Kentucky boosted its position in shares of ANI Pharmaceuticals by 5.4% in the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 3,881 shares of the specialty pharmaceutical company’s stock worth $209,000 after buying an additional 200 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of ANI Pharmaceuticals by 4.3% in the third quarter. The Manufacturers Life Insurance Company now owns 5,435 shares of the specialty pharmaceutical company’s stock valued at $316,000 after purchasing an additional 225 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of ANI Pharmaceuticals by 93.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 513 shares of the specialty pharmaceutical company’s stock valued at $30,000 after purchasing an additional 248 shares during the last quarter. Point72 Asset Management L.P. increased its stake in shares of ANI Pharmaceuticals by 60.0% during the 2nd quarter. Point72 Asset Management L.P. now owns 776 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 291 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of ANI Pharmaceuticals by 1.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 35,039 shares of the specialty pharmaceutical company’s stock worth $1,392,000 after purchasing an additional 384 shares in the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Price Performance

ANIP opened at $65.48 on Thursday. The stock has a fifty day moving average price of $64.60 and a 200 day moving average price of $58.52. The company has a current ratio of 3.57, a quick ratio of 2.81 and a debt-to-equity ratio of 0.66. ANI Pharmaceuticals, Inc. has a 1 year low of $36.99 and a 1 year high of $70.81. The stock has a market cap of $1.38 billion, a price-to-earnings ratio of 77.95 and a beta of 0.79.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. ANI Pharmaceuticals had a net margin of 3.86% and a return on equity of 18.06%. The firm had revenue of $131.65 million during the quarter, compared to analyst estimates of $123.02 million. Analysts forecast that ANI Pharmaceuticals, Inc. will post 3.55 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ANIP has been the topic of a number of analyst reports. HC Wainwright increased their target price on ANI Pharmaceuticals from $73.00 to $83.00 and gave the company a “buy” rating in a report on Monday, March 4th. Truist Financial raised their target price on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Capital One Financial assumed coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 15th. They set an “overweight” rating and a $80.00 price target for the company. Finally, Guggenheim lifted their price target on shares of ANI Pharmaceuticals from $70.00 to $77.00 and gave the company a “buy” rating in a report on Tuesday, March 5th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, ANI Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $80.00.

Insider Transactions at ANI Pharmaceuticals

In related news, COO Muthusamy Shanmugam sold 5,692 shares of the firm’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $55.95, for a total value of $318,467.40. Following the completion of the transaction, the chief operating officer now directly owns 897,620 shares of the company’s stock, valued at $50,221,839. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 7,787 shares of the firm’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $65.55, for a total transaction of $510,437.85. Following the completion of the transaction, the chief financial officer now owns 177,712 shares in the company, valued at $11,649,021.60. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Muthusamy Shanmugam sold 5,692 shares of ANI Pharmaceuticals stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $55.95, for a total value of $318,467.40. Following the sale, the chief operating officer now directly owns 897,620 shares in the company, valued at $50,221,839. The disclosure for this sale can be found here. In the last quarter, insiders have sold 145,686 shares of company stock valued at $9,586,490. 12.70% of the stock is owned by corporate insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.